Pulmonary arterial hypertension

Proceedings of the American Thoracic Society

Volumn 3, Issue 1, 2006, Pages 111-115

  Rubin, Lewis J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Endothelin; Prostacyclin; Pulmonary hypertension

Indexed keywords

ADENOSINE; AMBRISENTAN; ANTICOAGULANT AGENT; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIGOXIN; DIURETIC AGENT; ENDOTHELIN; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR ANTAGONIST; ILOPROST; NITRIC OXIDE; OXYGEN; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTANOID; SILDENAFIL; SITAXSENTAN; UNIPROST; WARFARIN;

ANEMIA; ANTICOAGULANT THERAPY; BLALOCK HANLON OPERATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DIAGNOSTIC PROCEDURE; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; EDEMA; FLUSHING; HEADACHE; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE OVERLOAD; HUMAN; INJECTION SITE PAIN; JAW DISEASE; LIVER TOXICITY; LUNG ANGIOGRAPHY; LUNG FUNCTION TEST; LUNG TRANSPLANTATION; MALE INFERTILITY; NAUSEA; OXYGEN THERAPY; PAIN; PULMONARY HYPERTENSION; RASH; REVIEW; SURGICAL TECHNIQUE; TERATOGENICITY; TESTIS ATROPHY; THROMBOSIS;

ANTIHYPERTENSIVE AGENTS; DIAGNOSIS, DIFFERENTIAL; HUMANS; HYPERTENSION, PULMONARY; LUNG TRANSPLANTATION; PULMONARY WEDGE PRESSURE; TREATMENT OUTCOME;

EID: 33644550641     PISSN: 15463222     EISSN: None     Source Type: Journal    
DOI: 10.1513/pats.200510-112JH     Document Type: Review

References (38)

1. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis E, Fischer SG, Barst RJ, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-744.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, Nichols JC, Trembath RC. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-84.
3. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship J, Simonneau G, Galie N, Loyd JE, Humbert M, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.
4. Newman JH, Wheeler L, Lane KB, Loyd E, Gaddipati R, Phillips JA, Loyd JE. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-324.
5. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott CG, Ward K, Yacoub M, Mikhail G, Rogers P, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR2, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-745.
6. Yuan JXJ, Rubin LJ. Pathogenesis of pulmonary artery hypertension: need for multiple hits. Circulation 2005;111:534-538.
7. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, Lang IM, Christman BW, Weir EK, Eickelberg O, Voelkel NF, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;12:13S-24S.
8. Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Koerner SK, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216.
9. McGoon M, Gutterman D, Steen V, Barst R, McCrory DC, Fortin TA, Loyd JE. Screening, early detection and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:14S-34S.
10. Fedullo PF, Auger WR, Kerr KM, Rubin LJ. Chronic thromboembolic pulmonary hypertension. N Engl J Med 2001;345:1465-1472.
11. Badesch DB, Abman SH, Ahearn GS, Barst RJ, McCrory DC, Simonneau G, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:35S-62S.
12. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:81S-88S.
13. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984;70:580-587.
14. Rich S, Kaufmann E, Levy PS. The effect of high doses of calciumchannel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76.
15. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al., for the Primary Pulmonary Hypertension Study Group. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
16. Badesch DB, Tapson VF,McGoon MD, Brundage BH, Rubin LJ,Wigley FM, Rich S, Barst RJ, Barrett PS, Kral KM, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med 2000;132:425-434.
17. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-1482.
18. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
19. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, et al; Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-804.
20. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, et al.; Aerosolized Iloprost Randomized Study Group. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-329.
21. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF,Badesch DB, Roux S, Rainisio M, Bodin F, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123.
22. Rubin LJ, Badesch DB, Barst RJ,Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan in patients with pulmonary arterial hypertension: a randomized placebo controlled multicenter study. N Engl J Med 2002;346:896-903.
23. Barst RJ, Langleben D, Frost A,Horn EM, Oudiz R, Shapiro S, McLaughlin VV, Hill N, Tapson VF, Robbins IM, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-447.
24. Galiè N, Badesch D, Oudiz R, Simonneau G, McGoon MD, Keogh A, Frost AE, Zwicke D, Naeije R, Shapiro S, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-535.
25. Michelakis E, Tymchak W, Lien D,Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
26. Atz AM, Wessel DL. Sildenafil ameliorates effects of inhaled nitric oxide withdrawal. Anesthesiology 1999;91:307-310.
27. Ghofrani HA, Wiedemann R, Rose F, Weissmann N, Schermuly RT, Quanz K, Grimminger F, Seeger W, Olschewski H. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002;136:515-522.
28. Galiè N, Ghofrani HN, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, et al. Sildenafil Citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-2157.
29. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN, Auger WR, Fedullo PF, Smith CM, Kriett JM, et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999;84:682-686.
30. Sandoval J, Gaspar J, Pulido T, Bantista E, Martinez-Guerra ML, Zeballos M, Palomar A, Gomez A. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998;32:297-304.
31. Mendeloff EN, Meyers BF, Sundt TM, Guthrie TJ, Sweet SC, de la Morena M, Shapiro S, Balzer DT, Trulock EP, Lynch JP, et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002;73:207-219.
32. Doyle RL, McCrory D, Channick RN, Simonneau G, Conte J. Surgical treatments/interventions for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:63S-71S.
33. Trulock EP, Edwards LB, Taylor DO, Boucek MM, Mohacsi PJ, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung and heart-lung transplant report - 2003. J Heart Lung Transplant 2003;22:625-635.
34. Hoeper MM, Oudiz RJ, Peacock A, Tapson VF, Haworth SG, Frost AE, Torbicki A. End points and clinical trial designs in pulmonary artery hypertension: clinical and regulatory perspectives. J Am Coll Cardiol 2004;43:48S-55S.
35. Raymond RJ,Hinderliter AL,Willis PW, Ralph D, Caldwell EJ,Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;39:1214-1219.
36. Dujardin KS, Tei C, Yeo TC, Hodge DO, Rossi A, Seward JB. Prognostic value of a Doppler index combining systolic and diastolic performance in idiopathic-dilated cardiomyopathy. Am J Cardiol 1998;82:1071-1076.
37. Yeo TC, Dujardin KS, Tei C, Mahoney DW, McGoon MD, Seward JB. Value of a Doppler-derived index combining systolic and diastolic time intervals in predicting outcome in primary pulmonary hypertension. Am J Cardiol 1998;81:1157-1161.
38. McLaughlin VV, Presberg KW, Doyle RL, Abman SH, McCrory DC, Fortin T, Ahearn G. Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S.